Bernstein reinstates Agilent with Outperform, $155 target

0 min read Updated on 26 Jun 2026, 07:01 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

Bernstein analyst Eve Burstein reinstated an Outperform rating on Agilent Technologies with a $155 price target.

*this image is generated using AI for illustrative purposes only.

Bernstein analyst Eve Burstein has reinstated an Outperform rating on Agilent Technologies, setting a price target of $155. The move signals renewed confidence in the company's stock performance following the rating adjustment.

Rating and Target Details

The reinstatement of the Outperform rating accompanies the specific price objective of $155. This valuation provides a reference point for investors regarding the stock's potential upside.

Analyst	Rating	Price Target
Eve Burstein (Bernstein)	Outperform	$155

What specific catalysts does Bernstein anticipate will drive Agilent's stock to the $155 price target?

How might Agilent's upcoming earnings report influence the sustainability of this Outperform rating?

What are the potential risks or market headwinds that could hinder Agilent from reaching this valuation?

Read Next Article

Excellere Partners and GHO Capital sell Biocare Medical to Agilent Technologies

1 min read Updated on 25 Jun 2026, 06:35 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

AI Summary

Excellere Partners and GHO Capital Partners LLP completed the sale of Biocare Medical to Agilent Technologies, Inc. on June 25, 2026. Under the sellers' ownership, Biocare achieved annual double-digit revenue and profitability growth. The acquisition aligns with Agilent's strategies in life sciences and diagnostics.

*this image is generated using AI for illustrative purposes only.

Excellere Partners and GHO Capital Partners LLP completed the sale of Biocare Medical to Agilent Technologies, Inc. on June 25, 2026. Biocare Medical is a global leader in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions. The transaction combines two businesses with aligned strategies in life sciences and diagnostics to enhance market access and innovation.

During the ownership of Excellere and GHO, Biocare delivered annual double-digit revenue and profitability growth. The company strengthened its core IHC business and expanded into molecular diagnostics through acquisitions. Additionally, the executive leadership team was reinforced, and the firm established strong commercial, regulatory, and R&D capabilities.

Strategic Alignment and Future Outlook

Agilent's acquisition of Biocare is expected to unlock greater market access and provide enhanced customer support. The combination aims to accelerate innovation for Biocare's customers worldwide. In a joint statement, Excellere and GHO highlighted the transaction as a significant milestone that resulted in a company with genuine transatlantic reach and a leading position in IHC solutions.

Key Stakeholders

Entity	Role	Details
Excellere Partners	Seller	Private equity firm based in Denver
GHO Capital Partners LLP	Seller	Specialist investor in global healthcare
Biocare Medical	Sold Entity	Global leader in IHC, ISH, and FISH solutions
Agilent Technologies, Inc.	Buyer	Listed on NYSE under ticker 'A'

Excellere Partners specializes in growth recapitalizations and management buyouts with $2.3 billion of committed capital. GHO Capital, based in London, is a specialist healthcare investment advisor. In May 2026, GHO Capital announced its combination with CBC Group, aiming to create the world’s largest dedicated healthcare investment manager with over $21 billion in assets under management, subject to regulatory approvals.

How will the integration of Biocare Medical’s molecular diagnostics portfolio impact Agilent’s competitive positioning in the precision oncology market?

What specific R&D synergies does Agilent anticipate from combining Biocare’s IHC capabilities with its existing life sciences and diagnostics platforms?

Will the completion of the GHO Capital and CBC Group merger proceed as planned following this successful exit, and how might it influence their future investment strategy?